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The order of potency of retinoids as inhibitors of A23 187-induced production of leukotriene B, (LTBJ in 
human polymorphonuclear leukocytes (PMN) was retinoic acid > retinal > retinol. However, the conver- 
sion of exogenous arachidonate (AA) to LTB, by PMN homogenates was inhibited in the rank order retinol 
> retinal >> retinoic acid. The agreement between active concentrations of retinol in these two systems 
is consistent with this compound acting directly to inhibit AA metabolism: this is not so for the other reti- 
noids. The order of potency for inhibition of phorbol dibutyrate (PDBu)-stimulated superoxide (0;) pro- 
duction in HL60 granulocytes was retinol > retinoic acid >> retinal (inactive); neither retinol nor retinal 
displaced [3H]PDBu from HL60 cells. We conclude that inhibition of LTB, production by retinoic acid and 
retinal is neither through inhibition of AA metabolism nor through inhibition of protein kinase C. 
Leukotriene Bb Retinoid; Superoxide; (Human leukocyte, HL60 cell) 
1. INTRODUCTION 
When PMN are stimulated at least two lipid 
pathways are activated. Diacylglycerol is produced 
from phosphatidylinositol 4,5bisphosphate [ 1,2] 
and endogenous arachidonic acid (AA) is mobi- 
lised [3]. Diacylglycerol activates a calcium- 
requiring phospholipid-dependent protein kinase 
C (PKC) [l], while AA mobilisation results in the 
rapid production of 5-L-hydroxy-ci.s-& l l , 14- 
trans-6-eicosatetraenoic a id (5HETE) and leuko- 
triene B4 (LTB4) [4]. Several studies have suggested 
links between these two pathways. The PKC ac- 
tivator 12-0-tetradecanoyl phorbol- 13-acetate 
(PMA) acts synergistically with the calcium iono- 
phore A23 187 in the_production of AA metabolites 
[5,6]. PMA also acts synergistically with lipoxy- 
genase (LO) products to evoke cellular responses 
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[7,8], and the LO product lipoxin has recently been 
reported to activate PKC [9]. 
Retinoids have a role in cancer chemotherapy 
and have been shown to inhibit the actions of 
tumour promotors both in vivo and in vitro 
[lO,ll]. In this context they have also been de- 
scribed as inhibitors of PKC [ 12,131. Retinoids are 
effective in the treatment of inflammatory skin 
diseases such as psoriasis, and the ability of 
retinoids to inhibit the generation of the chemotac- 
tic LO product LTB4 [ 14,151 has been implicated 
as a possible mode of action. Retinoids may 
therefore provide useful tools to investigate possi- 
ble links between PKC activation and AA 
metabolism. 
We have investigated the activities of retinoic 
acid, retinol, and retinal in inhibiting LTB4 genera- 
tion in both intact and homogenised PMN, and 
compared these with their activities against PDBu- 
stimulated 02 production in HL60 cells, a conve- 
nient and direct functional measurement of PKC 
activation [ 161. 
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2. MATERIALS AND METHODS 
2.1. L TB4 production 
Human PMN were prepared from freshly drawn 
blood. Erythrocytes were removed by sedimenta- 
tion at 37°C with 7.5 ml of 2% (w/v) methyl 
cellulose/100 ml blood. PMN were recovered by 
centrifugation (250 x g, 10 min) and residual 
erythrocytes were removed by lysis in 0.82% (w/v) 
NH&l + 5 mM KCl, pH 7.4. For intact-cell ex- 
periments PMN were washed in Hanks’ balanced 
salt solution containing 1 mM CaClz buffered to, 
pH 7.4, with 30 mM Hepes and were then suspend- 
ed at 10 x lo6 cells/ml. After equilibration at 37°C 
for 15 min, retinoids (Sigma) were added in 10 ~1 
DMSO. After incubation for 5 min, reactions were 
initiated by the addition of the calcium ionophore 
A23187 in DMSO (final concentration 1 PM). 
Reactions were terminated after 5 min by cen- 
trifugation (1000 x g, 3 min) and the supernatants 
were decanted for measurement of LTB4. 
For homogenate experiments, the PMN were 
washed in 50 mM sodium phosphate buffer, pH 
7.0, containing 1 mM EDTA and sonicated (3 x 
30 s, MSF Soniprep). Incubations were performed 
in 0.5 ml containing 5 x lo6 cell equivalents and 
0.94 mM EDTA. Retinoids were pre-incubated for 
5 min at 37°C with homogenate and reactions were 
started by the simultaneous addition of AA 
(Sigma) in ethanol (final concentration 5 PM) and 
CaC12 (final concentration 1 mM). Free Ca2+ con- 
centration was calculated to be 60pM. Reactions 
were terminated after 5 min by boiling. 
LTB4 was measured without extraction by 
specific radioimmunoassay [ 171. Mean LTB4 pro- 
duction in the absence of inhibitor was 2.67 +- 0.89 
(SE) ng/106 cells in intact cells (n = 7) and 7.32 f 
2.39 ng/106 cell equivalents in homogenates (n = 
3). 
2.2. Superoxide production 
HL60 granulocytes, grown in suspension culture 
in RPMI-1640 medium (Gibco) [16], were washed 
and resuspended at 0.3 x 106/ml in Hepes- 
buffered Hanks’ solution (pH 7.4). PDBu- 
stimulated 02 production was measured spec- 
trophotometrically as in [ 161. Retinoids and PDBu 
(100 nM) were each added in ethanol such that the 
final concentration of ethanol did not exceed 
0.2%. Mean PDBu-stimulated 0; release in the 
168 
absence of inhibitor was 4.92 + 0.24 (SE) 
nmol/106 cells per min (n = 3). 
2.3. ~HJPDBu binding 
Displacement of [3H]PDBu binding to undif- 
ferentiated HL60 cells by retinoids was measured 
as in [16]. 
3. RESULTS AND DISCUSSION 
Retinoids inhibited ionophore-induced LTB4 
production in intact PMN (fig.1). Retinoic acid 
(1C50 5 PM) was more potent than retinal (I& 
15 PM) and retinol (I&O 75 PM) was the least ac- 
tive. These results support the previously reported 
activity of retinoids although in rat PMN the rank 
order of potency was reported to be retinoic acid > 
retinol > retinal [14]. Our results in PMN 
homogenates how that inhibition of LTB4 pro- 
duction by retinol might be attributable to a direct 
effect on one of the enzymes that metabolises AA 
to LTB4. However, this is unlikely to be so for 
retinoic acid and retinal because the concentrations 
of these compounds required to inhibit LTB4 pro- 
Fig.1. Inhibition by retinoids of LTB4 production in 
intact (a) and homogenised (0) PMN. Each point 
represents mean * SE from 3-5 separate xperiments 
each in triplicate. 
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duction in PMN homogenates were lo-lOO-fold 
higher than were required in intact PMN. 
Therefore, the inhibition of ionophore-induced 
LTB4 production in intact PMN by retinoic acid 
and retinal was probably due to interference with 
a cellular activation mechanism triggered by the 
ionophore. 
Since it is known that PKC is activated by an 
elevation in intracellular calcium [18,19] and 
retinal has been described as an inhibitor of PKC 
[12,13], we compared the effects of retinoids on a 
leukocyte response stimulated by the PKC ac- 
tivator PDBu. PDBu-stimulated Or production by 
HL60 granulocytes was inhibited by retinol (IGO 
20pM) and retinoic acid (IGo > 30pM) (fig.2), 
but retinal was inactive at concentrations up to 
30,uM. Thus, the rank order of potency of 
retinoids for inhibition in this system (retinol > 
retinoic acid % retinal) contrasted with their rank 
order of potency for inhibition of ionophore- 
induced LTB4 production in PMN (retinoic acid > 
retinal > retinol). To characterise further the 
nature of the inhibition of PDBu-stimulated 02 
release in HL60 cells, retinol and retinal were 
tested for displacement of [3H]PDBu binding to in- 
tact HL60 cells (table 1). Neither compound 
displaced binding at concentrations up to 100 pM; 
if anything both compounds increased binding. 
Therefore, the inhibition by retinol of PDBu- 
stimulated 02 release cannot be explained by an 
interaction at the PDBu-binding site. 
It could be argued that, since the data for LTB4 
production and 02 release were obtained using dif- 
RETINAL RETINOL RETINOIC 
ACID 
CONC’N ($4) 
Fig.2. Inhibition by retinoids of PDBu-stimulated Or 
release by HL60 cells. The bars represent means f SE of 
6- 11 separate determinations. Shaded portions 
represent Oi release by retinoid alone. 
Table 1 
Displacement of t3H]PDBu binding to intact HL60 cells 
by retinol and retinal 
[3H]PDBu binding 
(fmol/106 cells) 
Total binding 73.4 f 10.7 
Retinal 
1pM 81.1 + 15.6 
10 PM 92.7 Z!I 20.8 
lOOaM 123.1 f 30.8 
Retinol 
1~cM 97.9 f 24.5 
1OpM 94.6 f 19.5 
1OOpM 145.4 + 29.0 
Results are means + SD from 3 experiments 
ferent cell types, direct comparison between the 
two systems can be made only with caution. 
However, HL60 cells are derived from human 
granulocytes and have been shown to be very 
similar to these both in terms of their functional 
responses [20,21] and their AA metabolism 
[22,23]. Since the rank orders of potency of 
retinoids for inhibition of LTB4 production and in- 
hibition of 02 release were not in agreement, we 
conclude that the two activities are unrelated, i.e. 
inhibition of ionophore-induced LTB4 production 
does not involve inhibition of PKC. Retinol in- 
hibits synthesis of LTB4 from AA but retinal and 
retinoic acid probably interfere with a cellular ac- 
tivation process, resulting in a reduction of AA 
mobilisation [24]. Retinal inhibited PDBu- 
stimulated 02 release by HL60 cells, a PKC- 
dependent process, but this effect was not through 
interaction with the PDBu-binding site. The lack 
of effect of retinal in this system contrasts with the 
observation of Taffet et al. [13]. Thus, further in- 
vestigation of the interaction between retinoids 
and PKC, especially the enzyme isolated from 
leukocytes, would be of interest. 
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